安杰思收盘上涨2.13%，滚动市盈率22.19倍，总市值65.86亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjiasi Medical Technology Co., Ltd., which operates in the medical device industry, specifically focusing on minimally invasive diagnostic and therapeutic instruments [1][2] - As of August 4, Anjiasi's stock closed at 81.33 yuan, reflecting a 2.13% increase, with a rolling price-to-earnings (PE) ratio of 22.19 times and a total market capitalization of 6.586 billion yuan [1] - The average PE ratio for the medical device industry is 54.32 times, with a median of 38.11 times, positioning Anjiasi at the 48th rank within the industry [1][2] Group 2 - As of July 31, 2025, Anjiasi has 5,365 shareholders, an increase of 202 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company specializes in the research, production, and sales of endoscopic minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - In the latest quarterly report for Q1 2025, Anjiasi reported a revenue of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.248 million yuan, reflecting a year-on-year growth of 6.57%, with a gross profit margin of 70.68% [1]